Open an account

Fortress Biotech

FBIO · NASDAQ

$1.94+$0.07 (+3.74%)TodayMarket closed ·
Prev close $1.87

About FBIO

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 78 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Employees
78
Headquarters
Bay Harbor Islands, Florida
Listed
Nov 17, 2011
Sector
Health Care
Industry
Biotechnology
Website
fortressbiotech.com

FBIO key statistics

Market cap
64.70M
Price-earnings ratio
0.00
Dividend yield
0.77%
Average volume
270.28K
Volume
293.96K
Open price
$1.88
High today
$1.95
Low today
$1.88
52 Week high
$4.53
52 Week low
$1.83

Fortress Biotech (FBIO) at a glance

As of Oct 20, 2026, Fortress Biotech (FBIO) shares are priced at $1.94, giving the company a market cap of 64.70M, a price-to-earnings ratio of 0.00 and a dividend yield of 0.77%.

Today the stock has traded between $1.88 and $1.95. The current price is 3.5% above the day's low and 0.5% below its high.

Volume so far is 293.96K shares, in line with the average of 270.28K shares a day.

Over the past year Fortress Biotech has ranged from $1.83 to $4.53, and now sits 4% of the way up that range.

Fortress Biotech met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.204.

The average analyst price target is $5.10, 162.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $5.10
Low
$5.05
Now
$1.94
High
$5.25

FBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 48.4% on average.

  1. Q3 FY24: reported -$0.76 per share against an estimate of -$0.6069
  2. Q4 FY24: reported -$0.75 per share against an estimate of -$0.7684
  3. Q1 FY25: reported -$0.48 per share against an estimate of -$0.5049
  4. Q2 FY25: reported -$0.50 per share against an estimate of -$0.3672
  5. Q3 FY25: reported $0.11 per share against an estimate of -$0.4284
  6. Q4 FY25: reported -$0.01 per share against an estimate of $0.1122
  7. Q1 FY26: reported -$1.13 per share against an estimate of -$0.2244
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.204

FBIO news

  • Press releaseGlobe Newswire

    Journey Medical Corporation to Participate in September 2026 Investor Conferences

  • Press releaseGlobe Newswire

    Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

  • Press releaseGlobe Newswire

    Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

  • Press releaseGlobe Newswire

    Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

  • Press releaseGlobe Newswire

    Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

  • Press releaseGlobe Newswire

    Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

  • Press releaseGlobe Newswire

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Similar companies

Companies in the same industry as Fortress Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.